Cargando…

Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study

PURPOSE: Intensive screening in BRCA1/2 mutation carriers aims to improve breast cancer (BC) prognosis. Our aim is to clarify the prognostic impact of tumor size in BRCA mutation carriers with a pT1 BC, which is currently unclear. We are especially interested in differences between pT1a, pT1b, and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Barele, Mark, Rieborn, Amy, Heemskerk-Gerritsen, Bernadette A. M., Obdeijn, Inge-Marie, Koppert, Linetta B., Loo, Claudette E., Tollenaar, Rob A. E. M., Ausems, Margreet G. E. M., van de Beek, Irma, Berger, Lieke P. V., de Boer, Maaike, van Hest, Liselot P., Kets, C. Marleen, Rookus, Matti, Schmidt, Marjanka K., Jager, Agnes, Hooning, Maartje J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167195/ https://www.ncbi.nlm.nih.gov/pubmed/35507134 http://dx.doi.org/10.1007/s10549-022-06608-1

Ejemplares similares

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers
por: Obdeijn, Inge-Marie, et al.
Publicado: (2020)

The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer
por: van Barele, Mark, et al.
Publicado: (2020)

Corrigendum to “The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer” [Breast 52 (2020) 102–109]
por: van Barele, Mark, et al.
Publicado: (2020)

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005)

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
por: de Jonge, Marthe M, et al.
Publicado: (2021)

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
por: Wevers, M. R., et al.
Publicado: (2015)

Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis
por: van den Broek, Alexandra J., et al.
Publicado: (2015)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation
por: van Barele, Mark, et al.
Publicado: (2023)

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
por: Mavaddat, Nasim, et al.
Publicado: (2020)

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
por: Mavaddat, Nasim, et al.
Publicado: (2020)

Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2022)

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers
por: van der Groep, Petra, et al.
Publicado: (2013)

Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers
por: Derks-Smeets, Inge A. P., et al.
Publicado: (2018)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium
por: Kast, Karin, et al.
Publicado: (2023)

Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?
por: van Barele, Mark, et al.
Publicado: (2021)

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
por: Olivier, R I, et al.
Publicado: (2004)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population
por: van den Broek, Alexandra J, et al.
Publicado: (2015)

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
por: Mohammadi, Leila, et al.
Publicado: (2009)

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits
por: Schrijver, Lieske H, et al.
Publicado: (2022)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis
por: Phi, Xuan-Anh, et al.
Publicado: (2016)

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history
por: Gómez García, Encarna B, et al.
Publicado: (2009)

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations
por: Terry, Mary Beth, et al.
Publicado: (2019)

Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences
por: Velthuizen, Mary E., et al.
Publicado: (2021)

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
por: Doebar, Shusma C., et al.
Publicado: (2016)

Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
por: Saadatmand, Sepideh, et al.
Publicado: (2012)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS)
por: Van Leeuwen, FE, et al.
Publicado: (2005)

BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy
por: Schlich-Bakker, Kathryn J., et al.
Publicado: (2007)

The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a BRCA1 or BRCA2 Germline Pathogenic Variant
por: Stuursma, Annechien, et al.
Publicado: (2023)

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)
por: Pijpe, Anouk, et al.
Publicado: (2012)

Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients
por: Papelard, H, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_1af6ospo4s4go02nordn7205lu